

DAFTAR PUSTAKA

Abdul Razzaque, M.R., Tebha, S.S., Tukruna, A., Arif, A., Kogut, L.M., Afsar, N.A., Shabbir, D., Zaidi, Z.A. 2023. 25-Hydroxyvitamin-D deficiency in chronic kidney disease stages III, IV, and V in South Asian population: a retrospective cohort. *SAGE Open Med*, 11:205031212211486.

Ademola, B.L., Atanda, A.T., Aji, S.A., Abdu, A. 2020. Clinical, morphologic and histological features of chronic pyelonephritis: An 8-year review. *Nigerian Postgraduate Medical Journal*, 27(1):37–41.

Ahmine, K., Benzid, C. 2021. Diagnosis of Disseminated Intravascular Coagulation University of Saad Dahlab Graduation Project Diagnosis of Disseminated Intravascular Coagulation Doctor of Pharmacy in, (January).

Akbulut, A.C., Arisz, R.A., Baaten, C.C.F.M.J., Baidildinova, G., Barakzie, A., Bauersachs, R., Berg, J. ten, van den Broek, W.W.A., Boer, H.C. de, Bonifay, A., Bröker, V., Buka, R.J., Cate, H. ten, Cate-Hoek, A.J. ten, Cointe, S., Luca, C. De, Simone, I. De, Diaz, R.V., Dignat-George, F., *et al.* 2022. Blood coagulation and beyond: Position paper from the Fourth Maastricht Consensus Conference on Thrombosis. *Thromb Haemost* [Preprint].

Alam, A., Doshi, H., Patel, D.N., Patel, K., James, D., Almendral, J. 2022. Myocardial infarction and factor VIII elevation in a 36-year-old man. *Baylor University Medical Center Proceedings*, 35(1):93–95.

Algahtani, F.H., Stuckey, R. 2019a. High factor VIII levels and arterial thrombosis: illustrative case and literature review. *Ther Adv Hematol*, 10:2040620719886685.

Algahtani, F.H., Stuckey, R. 2019b. High factor VIII levels and arterial thrombosis: illustrative case and literature review. *Ther Adv Hematol*, 10:2040620719886685.

Arruda, V.R. 2015. The search for the origin of factor viii synthesis and its impact on therapeutic strategies for hemophilia A. *Haematologica*, 100(7):849–850.

Aursulesei, V., Costache, I.I. 2019. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. *Clin Cardiol*. John Wiley and Sons Inc., 774–782.

Basaric, D., Saracevic, M., Bosnic, V., Vlatkovic, A., Tomic, B., Kovac, M. 2023a. Factor VIII Activity in Relation to the Type of Thrombosis and Patient's Risk Factors for Thrombosis, Age, and Comorbidity. *Eurasian Journal of Medicine*, 55(1):9–13.

Basaric, D., Saracevic, M., Bosnic, V., Vlatkovic, A., Tomic, B., Kovac, M. 2023b. Factor VIII Activity in Relation to the Type of Thrombosis and Patient's Risk Factors for Thrombosis, Age, and Comorbidity. *Eurasian Journal of Medicine*, 55(1):9–13.

Bauer, K.A., Lip, G.Y.H. 2017. Overview of the causes of venous thrombosis. *UpToDate*. Waltham [Preprint].



Analisis Faktor VIII Sebagai Faktor Risiko Hiperkoagulabilitas pada Pasien End Stage Renal Disease (ESRD) yang Menjalani Hemodialisis

Gusti Adheleida, Dr.dr. Usi Sukorini, M.Kes, SpPK(K), Dr.dr.Tri Ratnaningsih, M.Kes, SpPK(K)

Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

UNIVERSITAS
GADJAH MADA

Bernardi, F., Mariani, G. 2021. Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis. *Haematologica*, 106(2):351.

Biguzzi, E., Castelli, F., Lijfering, W.M., Cannegieter, S.C., Eikenboom, J., Rosendaal, F.R., van Hylckama Vlieg, A. 2021. Rise of levels of von Willebrand factor and factor VIII with age: role of genetic and acquired risk factors. *Thromb Res*, 197:172–178.

Bowyer, A.E., Gosselin, R.C. 2023. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments. *Semin Thromb Hemost*, 49(6):609–620.

Bucharles, S.G.E., Wallbach, K.K.S., de Moraes, T.P., Pecoits-Filho, R. 2019. Hypertension in patients on dialysis: diagnosis, mechanisms, and management. *Brazilian Journal of Nephrology*, 41(3):400–411.

Burton, A.G., Jandrey, K.E. 2020. Use of Thromboelastography in Clinical Practice. *Veterinary Clinics of North America - Small Animal Practice*, 50(6):1397–1409.

Câmara, N.O.S., Iseki, K., Kramer, H., Liu, Z.H., Sharma, K. 2017. Kidney disease and obesity: Epidemiology, mechanisms and treatment. *Nat Rev Nephrol*, 13(3):181–190.

Candeloro, M., Di Nisio, M., Valeriani, E., Auciello, R., La Barba, S., Guagnano, M.T., Caniglia, D., Schiavone, C., Guglielmi, M.D., Porreca, E. 2021. Effects of body composition on the procoagulant imbalance in obese patients. *J Thromb Thrombolysis*, 51(4):1036–1042.

Caughey, M.C., Derebail, V.K., Key, N.S., Reiner, A.P., Gottesman, R.F., Kshirsagar, A. V., Heiss, G. 2019. Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study. *Am J Hematol*, 94(12):1306–1313.

Cha, J., Han, D. 2020a. Health-related quality of life based on comorbidities among patients with end-stage renal disease. *Osong Public Health Res Perspect*, 11(4):194–200.

Cha, J., Han, D. 2020b. Health-related quality of life based on comorbidities among patients with end-stage renal disease. *Osong Public Health Res Perspect*, 11(4):194–200.

Chang, T.R., Albright, K.C., Boehme, A.K., Dorsey, A., Sartor, E.A., Kruse-Jarres, R., Leissinger, C., Martin-Schild, S. 2014a. Factor VIII in the setting of acute ischemic stroke among patients with suspected hypercoagulable state. *Clinical and Applied Thrombosis/Hemostasis*, 20(2):124–128.

Chang, T.R., Albright, K.C., Boehme, A.K., Dorsey, A., Sartor, E.A., Kruse-Jarres, R., Leissinger, C., Martin-Schild, S. 2014b. Factor VIII in the setting of acute ischemic stroke among patients with suspected hypercoagulable state. *Clinical and Applied Thrombosis/Hemostasis*, 20(2):124–128.

Chen, D., Daigh, C.A., Hendricksen, J.I., Pruthi, R.K., Nichols, W.L., Heit, J.A., Owen, W.G. 2008. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. *Journal of Thrombosis and Haemostasis*, 6(2):323–330.



Chen, X., Geng, X., Jin, S., Xu, J., Guo, M., Shen, D., Ding, X., Liu, H., Xu, X. 2021. The Association of Syndecan-1, Hypercoagulable State and Thrombosis and in Patients With Nephrotic Syndrome. *Clinical and Applied Thrombosis/Hemostasis*, 27.

Cheung, K.L., Bouchard, B.A., Cushman, M. 2018. Venous thromboembolism, factor VIII and chronic kidney disease. *Thromb Res*, 170(July):10–19.

Christiansen, S.C., Lijfering, W.M., Næss, I.A., Hammerstrøm, J., van Hylckama Vlieg, A., Rosendaal, F.R., Cannegieter, S.C. 2012. The relationship between body mass index, activated protein C resistance and risk of venous thrombosis. *Journal of Thrombosis and Haemostasis*, 10(9):1761–1767.

Corey, K.M., Olson, L.B., Naqvi, I.A., Morrison, S.A., Davis, C., Nimjee, S.M., Que, L.G., Bachelder, R.E., Kraft, B.D., Chen, L., Nair, S.K., Levy, J.H., Sullenger, B.A. 2022. Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. *Anesthesiology*, 137(1):67–78.

Costa, C., Alves, M., Durão, D., Leal, M., Monteiro, I. 2014. Elevated factor VIII in a patient with acute coronary syndrome, 33(3).

Cuker, A., Siegal, D.M., Crowther, M.A., Garcia, D.A. 2014. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. *J Am Coll Cardiol*, 64(11):1128–1139.

Darlington, A., Ferreira, J.L., Ueno, M., Suzuki, Y., Desai, B., Capranzano, P., Capodanno, D., Tello-Montoliu, A., Bass, T.A., Nahman, N.S., Angiolillo, D.J. 2011. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. *Thromb Haemost*, 106(1):67–74.

Devuyst, O., Olinger, E., Weber, S., Eckardt, K.-U., Knoch, S., Rampoldi, L., Bleyer, A.J. 2019. Autosomal dominant tubulointerstitial kidney disease. *Nat Rev Dis Primers*, 5(1):60.

Eikelboom, J., Floege, J., Thadhani, R., Weitz, J.I., Winkelmayer, W.C. 2021. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. *Kidney Int*, 100(6):1199–1207.

Esmon, C.T. 2005. The interactions between inflammation and coagulation. *Br J Haematol*, 131(4):417–430.

Esmon, C.T. 2009. Basic mechanisms and pathogenesis of venous thrombosis. *Blood Rev*, 23(5):225–229.

Everett, L.A., Cleuren, A.C.A., Khoriaty, R.N., Ginsburg, D. 2014. Murine coagulation factor VIII is synthesized in endothelial cells. *Blood*, 123(24):3697–3705.

Faustino, E.V.S., Li, S., Silva, C.T., Pinto, M.G., Qin, L., Tala, J.A., Rinder, H.M., Kupfer, G.M., Shapiro, E.D. 2015. FACTOR VIII MAY PREDICT CATHETER-RELATED THROMBOSIS IN CRITICALLY ILL CHILDREN: A PRELIMINARY STUDY, 16(6):497–504.



Furie, B., Furie, B.C. 2005. Thrombus formation in vivo. *J Clin Invest*, 115(12):3355–3362.

Gaipov, A., Issanov, A., Kadyrzhanuly, K., Galiyeva, D., Khvan, M., Aljofan, M., Molnar, M.Z., Kovesdy, C.P. 2020. Epidemiology of dialysis-treated end-stage renal disease patients in Kazakhstan: Data from nationwide large-scale registry 2014-2018. *BMC Nephrol*, 21(1):1–9.

Gale, A.J. 2011. Continuing Education Course #2: Current Understanding of Hemostasis. *Toxicol Pathol*, 39(1):273–280.

García-trabanino, R., Hernández, C., Rosa, A., Blanca, T., Salvador, E., Investigación, D. De, Rosales, H.N., Salvador, S., Salvador, E., Social, F., Emergencia, D., Blanca, C.T., Salvador, E., Salud, B. De, Sibasi, I., Salud, M. De, Salvador, E., Primaria, A., Sanitaria, Á., *et al.* 2016. Original article Incidence , mortality , and prevalence of end-stage chronic renal disease in the Bajo Lempa region of El Salvador : A ten-year community registry *℄*, 6(5):517–522.

Garmo, C., Bajwa, T., Burns, B. 2023. *Physiology, Clotting Mechanism*. Treasure I.

Gasparotto, M., Gatto, M., Binda, V., Doria, A., Moroni, G. 2020. Lupus nephritis: clinical presentations and outcomes in the 21st century. *Rheumatology*, 59(Supplement_5):v39–v51.

Gee, E. 2018. Principles and nursing management of anticoagulation. *Nursing Standard*, 32(23):50–63.

Goel, N., Jain, D., Haddad, D.B., Shanbhogue, D. 2020. Anticoagulation in patients with end-stage renal disease and atrial fibrillation: Confusion, concerns and consequences. *J Stroke*, 22(3):306–316.

Gonzalez, F., Paredes, H.J. 2013. Elevated Factor VIII Activity In Patients With Hypercoagulability Syndrome. *American Society of Hematology* [Preprint], (PATHOPHYSIOLOGY OF THROMBOSIS).

Gusev, E., Solomatina, L., Zhuravleva, Y., Sarapultsev, A. 2021. The pathogenesis of end-stage renal disease from the standpoint of the theory of general pathological processes of inflammation. *Int J Mol Sci*. MDPI.

Haemonetics. 2019. *Clinical Aid TEG 5000 Thromboelastograph Hemostasis System* . Haemonetics The Blood Management Company.

Hashmi, M.F., Benjamin, O., Lappin, S.L. 2018. End-stage renal disease.

Hoffman, M., Monroe, D.M. 2007. Coagulation 2006: a modern view of hemostasis. *Hematol Oncol Clin North Am*, 21(1):1–11.

Hoffman, M., Monroe, D.M. 2014. Reversing targeted oral anticoagulants. *Hematology (United States)*, 2014(1):518–523.



Analisis Faktor VIII Sebagai Faktor Risiko Hiperkoagulabilitas pada Pasien End Stage Renal Disease (ESRD) yang Menjalani Hemodialisis

Gusti Adheleida, Dr.dr. Usi Sukorini, M.Kes, SpPK(K), Dr.dr.Tri Ratnaningsih, M.Kes, SpPK(K)

Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

UNIVERSITAS
GADJAH MADA

Huang, M.J., Wei, R.B., Wang, Y., Su, T.Y., Di, P., Li, Q.P., Yang, X., Li, P., Chen, X.M. 2017. Blood coagulation system in patients with chronic kidney disease: A prospective observational study. *BMJ Open*, 7(5).

Jenkins, P.V., Rawley, O., Smith, O.P., O'Donnell, J.S. 2012. Elevated factor VIII levels and risk of venous thrombosis. *Br J Haematol*, 157(6):653–663.

Kamphuisen, P.W., Eikenboom, J.C.J., Bertina, R.M. 2001. Elevated factor VIII levels and the risk of thrombosis. *Arterioscler Thromb Vasc Biol*, 21(5):731–738.

KDIGO, K.D.I.G.O. 2024. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Official Journal of the International Society of Nephrology*, 105(45):S117–S314.

Khandelwal, D., Mathur, V., Vyas, A., Shah, C., Ranawat, C.S., Patel, P. 2021. Elevated factor VIII levels and arterial stroke: a review of literature with a case report. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 57(1):4–9.

Kim, S., Kim, M.J., Gu, J., Kim, H.K. 2022. Influence of Blood Coagulation Factors on Thromboelastographic Parameters in Healthy Adults. *Laboratory Medicine Online*, 12(2):109–115.

Knoll, G.A., Wells, P.S., Young, D., Perkins, S.L., Pilkey, R.M., Clinch, J.J., Rodger, M.A. 2005. Thrombophilia and the risk for hemodialysis vascular access thrombosis. *Journal of the American Society of Nephrology*, 16(4):1108–1114.

Kohli, R., Platton, S., Forbes, S., Thuraisingham, R., Tan, J., Green, L., MacCallum, P. 2023. Renal transplant and hemostasis: early postoperative changes in recipients and donors. *Res Pract Thromb Haemost*, 7(4).

Koltsova, E.M., Sorokina, M.A., Pisaryuk, A.S., Povalyaev, N.M., Ignatova, A.A., Polokhov, D.M., Kotova, E.O., Balatskiy, A. V., Ataulakhanov, F.I., Panteleev, M.A., Kobalava, Z.D., Balandina, A.N. 2021. Hypercoagulation detected by routine and global laboratory hemostasis assays in patients with infective endocarditis. *PLoS One*, 16(12 December).

Konkle, B.A., Shapiro, A.D., Quon, D. V, Staber, J.M., Kulkarni, R., Ragni, M. V, Chhabra, E.S., Poloskey, S., Rice, K., Katragadda, S. 2020. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. *New England Journal of Medicine*, 383(11):1018–1027.

Kornblith, L.Z., Howard, B., Kunitake, R., Redick, B., Nelson, M., Cohen, M.J., Callcut, R. 2015. Obesity and clotting: Body mass index independently contributes to hypercoagulability after injury. *Journal of Trauma and Acute Care Surgery*, 78(1):30–36.

Kurniawan, A.W., Koesrini, J. 2019. Hubungan Kadar Ureum, Hemoglobin dan Lama Hemodialisa dengan Kualitas Hidup Penderita PGK. *Jurnal Ners dan Kebidanan (Journal of Ners and Midwifery)*, 6(3):292–299.



Lai, T.S., Hsu, C.C., Lin, M.H., Wu, V.C., Chen, Y.M. 2022. Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010–2018. *Journal of the Formosan Medical Association*, 121:S5–S11.

Lambert, M.P. 2016. Platelets in liver and renal disease. *Hematology*, 2016(1):251–255.

LaPelusa, A., Dave, H.D. 2023. Physiology, Hemostasis. *Treasure Island (FL): StatPearls Publishing* [Preprint].

Levi, M., van der Poll, T. 2017. Coagulation and sepsis. *Thromb Res*, 149:38–44.

Lew, Q.L.J., Jafar, T.H., Talaei, M., Jin, A., Chow, K.Y., Yuan, J.M., Koh, W.P. 2017. Increased body mass index is a risk factor for end-stage renal disease in the Chinese Singapore population. *Kidney Int*, 92(4):979–987.

Lim, H.Y., Lui, B., Tacey, M., Barit, D., Patel, S.K., Donnan, G., Nandurkar, H., Burrell, L.M., Ho, P. 2023. Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk. *Thromb Res*, 226:127–135.

Lordan, R., Tsoupras, A., Zabetakis, I. 2021. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. *Blood Rev*, 45:100694.

Lu, M., Blaine, K.P., Cullinane, A., Hall, C., Dulau-Florea, A., Sun, J., Chenwi, H.F., Graninger, G.M., Harper, B., Thompson, K., Krack, J., Barnett, C.F., Brusca, S.B., Elinoff, J.M., Solomon, M.A. 2021. Pulmonary arterial hypertension patients display normal kinetics of clot formation using thrombelastography. *Pulm Circ*, 11(3).

Lutz, J., Menke, J., Sollinger, D., Schinzel, H., Thürmel, K. 2014. Haemostasis in chronic kidney disease. *Nephrology Dialysis Transplantation*, 29(1):29–40.

Mackman, N. 2008. Triggers, targets and treatments for thrombosis. *Nature*, 451(7181):914–918.

Mackman, N., Bergmeier, W., Stouffer, G.A., Weitz, J.I. 2020. Therapeutic strategies for thrombosis: new targets and approaches. *Nat Rev Drug Discov*, 19(5):333–352.

Made, N., Pasek, A.L., Ristyning Ayu, P., Carolia, N. 2019. Perbedaan Kadar Hemoglobin pada Pasien End Stage Renal Disease (ESRD) Sebelum dan Setelah Mendapat Terapi Eritropoietin di RSUD Dr. H. Abdul Moeloek Bandar Lampung. *Medula*, 9(3):533–537.

Madhusudhan, T., Kerlin, B.A., Isermann, B. 2016. The emerging role of coagulation proteases in kidney disease. *Nat Rev Nephrol*, 12(2):94–109.

Marlar, R.A., Gausman, J.N. 2014. Laboratory testing issues for protein C, protein S, and antithrombin. *Int J Lab Hematol*, 36(3):289–295.

Mayne, E.E., Bridges, J.M., Weaver, J.A. 1970. Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitus. *Diabetologia*, 6(4):436–440.



Morfini, M., Coppola, A., Franchini, M., Minno, G. Di. 2013. Clinical use of factor VIII and factor IX concentrates. *Blood Transfusion*.

Mukhyarjon, Wahid, I., Manaf, A. 2020. Profil dan Beberapa Faktor yang Berhubungan dengan Hemostasis Pasien Diabetes Melitus Tipe 2 Tak Terkontrol. *Jurnal Kedokteran dan Kesehatan*, 16(2):128–135. Available at: <https://jurnal.umj.ac.id/index.php/JKK>.

Muslimovic, A., Rasic, S., Tulumovic, D., Hasanspahic, S., Rebic, D. 2015. Inflammatory Markers and Procoagulants in Chronic Renal Disease Stages 1-4. *Med Arch*, 69(5):307–310.

Nampoory, M.R.N., Das, K.C., Johny, K. V, Al-Hilali, N., Abraham, M., Easow, S., Saed, T., Al-Muzeirei, I.A., Sugathan, T.N., Al Mousawi, M. 2003. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. *American Journal of Kidney Diseases*, 42(4):797–805.

Negreva, M., Prodanova, K., Vitlianova, K., Madjova, C. 2020a. Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability. *Archives of Medical Science – Atherosclerotic Diseases*, 5(1):140–147.

Negreva, M., Prodanova, K., Vitlianova, K., Madjova, C. 2020b. Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability. *Archives of Medical Science – Atherosclerotic Diseases*, 5(1):140–147.

Ocak, G., Vossen, C.Y., Lijfering, W.M., Verduijn, M., Dekker, F.W., Rosendaal, F.R., Cannegieter, S.C. 2014. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function. *Circulation*, 129(6):683–691.

Ocelli, F., Deram, A., Génin, M., Noël, C., Cuny, D., Glowacki, F., Aazib, L., Benziane, A., Bonnard, G., Burda, G., Macnamara, E., Ratsimbazafy, A., Skalli, A., Wajsbrodt, L., Bataille, P., Billion, S., Botte-Noël, A., Daroux, M., Mesbah, R., *et al.* 2014. Mapping end-stage renal disease (ESRD): Spatial variations on small area level in northern france, and association with deprivation. *PLoS One*, 9(11).

Olivo, R.E., Davenport, C.A., Diamantidis, C.J., Bhavsar, N.A., Tyson, C.C., Hall, R., Bidulescu, A., Young, B., Mwasongwe, S.E., Pendergast, J., Boulware, L.E., Scialla, J.J. 2018. Obesity and synergistic risk factors for chronic kidney disease in African American adults: the Jackson Heart Study. *Nephrology Dialysis Transplantation*, 33(6):992–1001.

O’Shea, S.I., Lawson, J.H., Reddan, D., Murphy, M., Ortel, T.L. 2003. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. *J Vasc Surg*, 38(3):541–548.

Padda, I.S., Patel, P., Sridhar, D.C. 2023. Protein C and S. *National Library of Medicine* [Preprint]. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK557814/>.

Padmanabhan, A., Gohil, S., Gadgil, N.M., Sachdeva, P. 2017. Chronic renal failure: An autopsy study. *Saudi Journal of Kidney Diseases and Transplantation*, 28(3):545–551.

Palta, S., Saroa, R., Palta, A. 2014. Overview of the coagulation system. *Indian J Anaesth*, 58(5):515–523.

Pandey, C.K., Prakash, K., Karna, S.T., Nayak, S.L., Tandon, M., Jain, P. 2019. Detection of coagulopathy in chronic renal disease using thromboelastography and its comparison with conventional tests. *Journal of Association of Physicians of India*, 67(June):34–37.

Pénzes, K., Hurják, B., Katona, É., Becs, G., Balla, J., Muszbek, L. 2020. Terminal phase components of the clotting cascade in patients with end-stage renal disease undergoing hemodiafiltration or hemodialysis treatment. *Int J Mol Sci*, 21(22):1–15.

Pradhan-Sundd, T., Gudapati, S., Kaminski, T.W., Ragni, M. V. 2021. Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease. *Cmgh*, 12(3):1061–1072.

Quencer, K.B., Oklu, R. 2017. Hemodialysis access thrombosis. *Cardiovasc Diagn Ther*, 7(Suppl 3):S299–S308.

Rabei, R. 2022. Hemodialysis Access Interventions. *In: Essential Interventional Radiology Review*. Cham: Springer International Publishing, 379–388.

Raffield, L.M., Lu, A.T., Szeto, M.D., Little, A., Grinde, K.E., Shaw, J., Auer, P.L., Cushman, M., Horvath, S., Irvin, M.R., Lange, E.M., Lange, L.A., Nickerson, D.A., Thornton, T.A., Wilson, J.G., Wheeler, M.M., Zakai, N.A., Reiner, A.P. 2020. Coagulation factor VIII: Relationship to cardiovascular disease risk and whole genome sequence and epigenome-wide analysis in African Americans. *Journal of Thrombosis and Haemostasis*, 18(6):1335–1347.

Rau, J.C., Beaulieu, L.M., Huntington, J.A., Church, F.C. 2007. Serpins in thrombosis, hemostasis and fibrinolysis. *Journal of Thrombosis and Haemostasis*, 5(SUPPL. 1):102–115.

Registry, I.R. 2020. 13 th ANNUAL REPORT OF INDONESIA RENAL REGISTRY.

Ribic, C., Crowther, M. 2016. Thrombosis and anticoagulation in the setting of renal or liver disease. *American Society of Hematology*, 1(1):188–196. Available at: <http://ashpublications.org/hematology/article-pdf/2016/1/188/1250707/hem088408.pdf>.

Rietveld, I.M., Lijfering, W.M., le Cessie, S., Bos, M.H.A., Rosendaal, F.R., Reitsma, P.H., Cannegieter, S.C. 2019. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. *Journal of Thrombosis and Haemostasis*, 17(1):99–109.

Robbins, Kumar. 2022. *Basic Pathology*. 11th edn. Edited by Vinay Kumar *et al*.

Samai, A.A., Boehme, A.K., Shaban, A., George, A.J., Dowell, L., Monlezun, D.J., Leissinger, C., Schluter, L., El Khoury, R., Martin-Schild, S. 2016. A Model for Predicting Persistent Elevation of Factor VIII among Patients with Acute Ischemic Stroke. *J Stroke Cerebrovasc Dis.*, 25(2):428–435.

Scheiner, B., Northup, P.G., Lisman, T., Mandorfer, M. 2020. Author response to Letter to the Editor: ‘AB0, von Willebrand factor/Factor VIII and portal vein thrombosis in



decompensated cirrhosis: Too late to unmask the culprit?' *Liver International*, 40(7):1790–1791.

Scheiner, B., Balcar, L., Nussbaumer, R.J., Weinzierl, J., Paternostro, R., Simbrunner, B., Hartl, L., Jachs, M., Bauer, D., Stättermayer, A.F., Semmler, G., Pinter, M., Ay, C., Quehenberger, P., Trauner, M., Reiberger, T., Lisman, T., Mandorfer, M. 2022. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. *J Hepatol*, 76(5):1090–1099.

Sehgal, T., Aggarwal, M., Baitha, U., Gupta, G., Prakash, B., Gupta, A., Kumar, G., Biswas, A., Khan, M., Shalimar, D.M. 2022. Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019. *Res Pract Thromb Haemost*, 6(1).

Serrano, RE.T., Tamayo, HE.B. 2021. Thromboelastographic alterations in patients with dialytic urgency. *Rev. Colomb. Nefrol.*, 8(2):e542.

Sertsu, A., Worku, T., Fekadu, G., Tura, A.K. 2022. Prevalence of chronic kidney disease and associated factors among patients visiting renal unit of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia: A cross-sectional study design. *SAGE Open Med*, 10:205031212211169.

Shah, R., Haddad, N., Vachharajani, T.J., Asif, A., Agarwal, A. 2014. Thrombocytopenia in ESRD patients: Epidemiology, mechanisms and interventional nephrology perspective. *Semin Dial*, 27(6):618–625.

Shaydakov, M.E., Sigmon, D.F., Blebea, J. 2022. *Thromboelastography*. Treasure Island (FL): StatPearls Publishing.

Shaydakov, M.E., Sigmon, D.F., Blebea J. 2023. *Thromboelastography - StatPearls - NCBI Bookshelf*. Treasure Island (FL): StatPearls Publishing. Treasure Island (FL): StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK537061/> (Accessed: 21 February 2023).

Shen, B.W., Spiegel, P.C., Chang, C.-H., Huh, J.-W., Lee, J.-S., Kim, J., Kim, Y.-H., Stoddard, B.L. 2008. The tertiary structure and domain organization of coagulation factor VIII. *Blood, The Journal of the American Society of Hematology*, 111(3):1240–1247.

Singh, J., Khadka, S., Solanki, D., Kichloo, A., Shah, H., Vyas, Manasee J., Chugh, S., Patel, N., Solanki, S. 2021. Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States. *SAGE Open Med*, 9.

Singh, J., Khadka, S., Solanki, D., Kichloo, A., Shah, H., Vyas, Manasee J, Chugh, S., Patel, N., Solanki, S. 2021. Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States. *SAGE Open Med*, 9:205031212110229.

Smith, S.A., Travers, R.J., Morrissey, J.H. 2016. How it all starts: initiation of the clotting cascade Stephanie. *HHS Public Access*, 50(4):326–336.

- Stassen, J.M., Arnout, J., Deckmyn, H. 2004. The Hemostatic System, 2245–2260.
- Streiff, M.B. 2023. *Elevated Factor VIII, IX, and XI Levels. MSD Manual Professional Version; Merck & Co., Inc., Rahway, NJ, USA and its affiliates*. Available at: <https://www.msdmanuals.com/professional/hematology-and-oncology/thrombotic-disorders/elevated-factor-viii,-ix,-and-xi-levels>.
- Tabatabai, A., Rabin, J., Menaker, J., Madathil, R., Galvagno, S., Menne, A., Chow, J.H., Grazioli, A., Herr, D., Tanaka, K., Scalea, T., Mazzeffi, M. 2020. Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series. *A Pract*, 14(7):e01236.
- Thakur, M., Ahmed, A.B. 2012. A review of thromboelastography. *International Journal of Perioperative Ultrasound and Applied Technologies*, 1(1):25–29.
- Thomson, P.C., Mark, P.B., Robertson, M., White, C., Anker, S.D., Bhandari, S., Farrington, K., Jardine, A.G., Kalra, P.A., McMurray, J., Reddan, D., Wheeler, D.C., Winearls, C.G., Ford, I. 2022. An Analysis of Vascular Access Thrombosis in hemodiALysis Patients Trial, 5:1793–1801.
- Timp, J.F., Lijfering, W.M., Flinterman, L.E., van Hylckama Vlieg, A., le Cessie, S., Rosendaal, F.R., Cannegieter, S.C. 2015. Predictive value of factor VIII levels for recurrent venous thrombosis: Results from the MEGA follow-up study. *Journal of Thrombosis and Haemostasis*, 13(10):1823–1832.
- Torreggiani, M., Fois, A., Njandjo, L., Longhitano, E., Chatrenet, A., Esposito, C., Fessi, H., Piccoli, G.B. 2021. Toward an individualized determination of dialysis adequacy: a narrative review with special emphasis on incremental hemodialysis. *Expert Rev Mol Diagn*, 21(11):1119–1137.
- Tripodi, A., Lombardi, R., Primignani, M., La Mura, V., Peyvandi, F., Fracanzani, A.L. 2022. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. *Biomedicines*. MDPI.
- Tuegel, C., Katz, R., Alam, M., Bhat, Z., Bellovich, K., de Boer, I., Brosius, F., Gadegbeku, C., Gipson, D., Hawkins, J. 2018. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. *American Journal of Kidney Diseases*, 72(4):519–528.
- Umar, I., Sujud, R.W. 2020. Hemostasis dan Disseminated Intravascular Coagulation (DIC), 1(2):19–32.
- Wahid, I., Manaf, A. no date. *Profil dan Beberapa Faktor yang Berhubungan dengan Hemostasis Pasien Diabetes Melitus Tipe 2 Tak Terkontrol*. Available at: <https://jurnal.umj.ac.id/index.php/JKK>.
- Wahyudi, I.E.D., Pujo, J.L. 2012. ANGKA KEMATIAN PASIEN END STAGE RENAL DISEASE DI ICU DAN HCU RSUP DR. KARIADI. *JURNAL MEDIA MEDIKA MUDA*, 1(1):1–13.



Analisis Faktor VIII Sebagai Faktor Risiko Hiperkoagulabilitas pada Pasien End Stage Renal Disease (ESRD) yang Menjalani Hemodialisis

Gusti Adheleida, Dr.dr. Usi Sukorini, M.Kes, SpPK(K), Dr.dr.Tri Ratnaningsih, M.Kes, SpPK(K)

Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

UNIVERSITAS
GADJAH MADA

Wanaratwicit, P., Chai-Adisaksopha, C., Inmutto, N., Noppakun, K. 2023. Risk factors of worsening kidney function and mortality in patients with renal vein thrombosis: a retrospective study. *J Nephrol* [Preprint].

Wei, C., Zhao, J.-Y., Wang, S.-Y., Sun, H.-N., Guan, N.-Z. 2022. Establishment of normal reference range for thromboelastography based on 17,708 cases in Beijing, China. *Ann Transl Med*, 10(10):550–550.

Weitz, J.I., Bates, S.M. 2005. New anticoagulants. *Journal of Thrombosis and Haemostasis*, 3(8):1843–1853.

Wright, F.L., Vogler, T.O., Moore, E.E., Moore, H.B., Wohlauer, M. V., Urban, S., Nydam, T.L., Moore, P.K., McIntyre, R.C. 2020. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. *J Am Coll Surg*, 231(2):193-203.e1.

Wu, T., Tang, L. V., Hu, Y. 2022. Venous Thromboembolism in Kidney Diseases and Genetic Predisposition. *Kidney Diseases*, 8(3):181–189.

Yeh, C.H., De Wit, K., Levy, J.H., Weitz, J.I., Vaezzadeh, N., Liaw, P.C., Fox-Robichaud, A., Soliman, K., Kim, P.Y. 2020. Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. *Journal of Trauma and Acute Care Surgery*, 89(6):e177–e181.

Yi-fan, L., Dai-jun, X., Hong-wei, T., Hong-rui, Z., Xiao-li, W., Yin-jing, X., Mian-yang, L., Cheng-bin, W., Deng-qing, L. 2013. Thrombelastography and coagulation parameters in chronic kidney disease patients and their clinical significance.

Zhu, Q., Scherer, P.E. 2018. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. *Nat Rev Nephrol*, 14(2):105–120.

Zia, A.N., Bilal, M.F., Rajpurkar, M., Chitlur, M.B., Callaghan, M., Lusher, J.M. 2011. The Utility of Thromboelastography As a Screening Test for Bleeding Disorders. *Blood*, 118(21):4352–4352.